Zydus Group, of Ahmedabad, India, said it started phase III trials of Lipaglyn (saroglitazar) in patients with lipodystrophy, with the goal of evaluating the drug's safety and efficacy vs. standard of care with placebo. Lipaglyn previously gained approval in India for treating diabetic dyslipidemia and hypertriglyceridemia.